Maleesha Jayasinghe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maleesha Jayasinghe has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Ana Leticia Fornari Caprara
Neurology, Universidade Federal de Santa Maria, Santa Maria, BRA
3 shared publicationsFatemeh Rashidi
Medical School, Nanjing Medical University, Nanjing, CHN
3 shared publicationsHania Moharam
Medicine and Surgery, Nanjing Medical University, Nanjing, CHN
3 shared publicationsJamir Pitton Rissardo
Neurology, Cooper University Hospital, Camden, USA
3 shared publicationsMasoumeh Rashidi
Medical School, Nanjing Medical University, Nanjing, CHN
3 shared publicationsOmesh Prathiraja
Medicine and Surgery, Nanjing Medical University, Nanjing, CHN
3 shared publications
Latest Publications
- Open Access
- 22 July 2025
- Published by Springer Nature in Cureus
- Vol. 17 (7) , e88487
Intersection of Autonomic Dysfunction and Parkinson’s Disease: Insights Into Neurogenic and Classical Orthostatic Hypotension
Neurogenic orthostatic hypotension (nOH) and classical orthostatic hypotension (OH) are prevalent non-motor manifestations of Parkinson’s disease (PD). They can significantly impact quality of life, increasing the risk of falls, cognitive decline, and functional impairment. Despite the high prevalence and clinical impact of neurogenic orthostatic hypotension and OH in PD, no comprehensive consensus integrates recent advances in pathophysiology, diagnostic tools, and personalized treatment. This review synthesizes current evidence to bridge this gap, offering a practical framework for clinicians to improve patient outcomes. Neurogenic orthostatic hypotension in PD results from complex interactions between central and peripheral autonomic dysfunction, alpha-synuclein accumulation, baroreflex failure, and medication effects. Its prevalence increases with disease progression and age. Clinical evaluation remains the cornerstone of diagnosis, supported by specialized testing such as the active standing test, ambulatory blood pressure monitoring, and autonomic function assessments. Management requires a tailored approach, combining non-pharmacologic strategies, such as fluid and salt intake optimization, compression garments, and physical counter-maneuvers, with pharmacological treatments, including midodrine, droxidopa, and fludrocortisone. Emerging therapies and ongoing clinical trials offer promising avenues for future interventions. Early recognition and individualized management of OH are critical in PD care.
- 22 July 2025
- Published by Springer Nature in Cureus
- Vol. 17 (7) , e88487
Open AccessIntersection of Autonomic Dysfunction and Parkinson’s Disease: Insights Into Neurogenic and Classical Orthostatic Hypotension
Neurogenic orthostatic hypotension (nOH) and classical orthostatic hypotension (OH) are prevalent non-motor manifestations of Parkinson’s disease (PD). They can significantly impact quality of life, increasing the risk of falls, cognitive decline, and functional impairment. Despite the high prevalence and clinical impact of neurogenic orthostatic hypotension and OH in PD, no comprehensive consensus integrates recent advances in pathophysiology, diagnostic tools, and personalized treatment. This review synthesizes current evidence to bridge this gap, offering a practical framework for clinicians to improve patient outcomes. Neurogenic orthostatic hypotension in PD results from complex interactions between central and peripheral autonomic dysfunction, alpha-synuclein accumulation, baroreflex failure, and medication effects. Its prevalence increases with disease progression and age. Clinical evaluation remains the cornerstone of diagnosis, supported by specialized testing such as the active standing test, ambulatory blood pressure monitoring, and autonomic function assessments. Management requires a tailored approach, combining non-pharmacologic strategies, such as fluid and salt intake optimization, compression garments, and physical counter-maneuvers, with pharmacological treatments, including midodrine, droxidopa, and fludrocortisone. Emerging therapies and ongoing clinical trials offer promising avenues for future interventions. Early recognition and individualized management of OH are critical in PD care.
- Open Access
- 25 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3) , e81129
Exploring Fatigue in Parkinson’s Disease: A Comprehensive Literature Review
Fatigue is one of the most prevalent and debilitating non-motor symptoms of Parkinson’s disease (PD), affecting up to two-thirds of patients and significantly impacting quality of life. This review provides a comprehensive analysis of its complex pathophysiology, prevalence, clinical presentation, assessment methods, and current management strategies. Fatigue in PD is linked to dysfunction in dopaminergic and non-dopaminergic pathways, neuroinflammation, genetic predispositions, and metabolic dysregulation. Reported prevalence rates range from 36% to 60%, highlighting the need for standardized assessment tools and a universally accepted definition. Clinically, fatigue is characterized by an overwhelming and abnormal sense of exhaustion, often preceding motor symptoms by years. Distinguishing it from sleepiness, apathy, and depression is crucial for accurate diagnosis and treatment. Assessment primarily relies on patient-reported scales, such as the Fatigue Severity Scale and the Parkinson’s Disease Fatigue Scale. Management includes both pharmacological and non-pharmacological approaches, with medications like methylphenidate and rasagiline showing potential, alongside physical exercise, cognitive behavioral therapy, and sleep disorder management. Further research is essential to unravel the underlying mechanisms, identify objective biomarkers, and develop more effective, targeted treatments for this burdensome symptom.
- 25 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3) , e81129
Open AccessExploring Fatigue in Parkinson’s Disease: A Comprehensive Literature Review
Fatigue is one of the most prevalent and debilitating non-motor symptoms of Parkinson’s disease (PD), affecting up to two-thirds of patients and significantly impacting quality of life. This review provides a comprehensive analysis of its complex pathophysiology, prevalence, clinical presentation, assessment methods, and current management strategies. Fatigue in PD is linked to dysfunction in dopaminergic and non-dopaminergic pathways, neuroinflammation, genetic predispositions, and metabolic dysregulation. Reported prevalence rates range from 36% to 60%, highlighting the need for standardized assessment tools and a universally accepted definition. Clinically, fatigue is characterized by an overwhelming and abnormal sense of exhaustion, often preceding motor symptoms by years. Distinguishing it from sleepiness, apathy, and depression is crucial for accurate diagnosis and treatment. Assessment primarily relies on patient-reported scales, such as the Fatigue Severity Scale and the Parkinson’s Disease Fatigue Scale. Management includes both pharmacological and non-pharmacological approaches, with medications like methylphenidate and rasagiline showing potential, alongside physical exercise, cognitive behavioral therapy, and sleep disorder management. Further research is essential to unravel the underlying mechanisms, identify objective biomarkers, and develop more effective, targeted treatments for this burdensome symptom.
- Open Access
- 21 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77799
Exploring the Neurological Manifestations of Leprosy: Clinical Insights and Implications
Leprosy is one of the neglected tropical diseases, and its elimination remains a public health problem globally. This manuscript comprehensively explores the neurological manifestations of leprosy, offering clinical insights and implications for the diagnosis, management, and understanding of this disease. Beginning with a review of historical context, etiology, and epidemiology, we delve into the pathophysiology of leprosy neuropathy, highlighting mechanisms of nerve damage and immune response. Peripheral nerve involvement, including sensory and motor deficits, nerve enlargement, and deformities, are discussed in detail, along with the challenges in diagnosis and management. Psychological and social implications of neurological deficits in leprosy are addressed, emphasizing the importance of holistic care and support. Emerging trends in neuroimaging and molecular diagnostics offer promising avenues for improved diagnosis and therapeutic interventions. Novel therapeutic strategies are identified to enhance treatment efficacy and prevent disability in leprosy neuropathy by targeting immunomodulatory pathways, antibacterial agents, and a personalized medicine approach.
- 21 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77799
Open AccessExploring the Neurological Manifestations of Leprosy: Clinical Insights and Implications
Leprosy is one of the neglected tropical diseases, and its elimination remains a public health problem globally. This manuscript comprehensively explores the neurological manifestations of leprosy, offering clinical insights and implications for the diagnosis, management, and understanding of this disease. Beginning with a review of historical context, etiology, and epidemiology, we delve into the pathophysiology of leprosy neuropathy, highlighting mechanisms of nerve damage and immune response. Peripheral nerve involvement, including sensory and motor deficits, nerve enlargement, and deformities, are discussed in detail, along with the challenges in diagnosis and management. Psychological and social implications of neurological deficits in leprosy are addressed, emphasizing the importance of holistic care and support. Emerging trends in neuroimaging and molecular diagnostics offer promising avenues for improved diagnosis and therapeutic interventions. Novel therapeutic strategies are identified to enhance treatment efficacy and prevent disability in leprosy neuropathy by targeting immunomodulatory pathways, antibacterial agents, and a personalized medicine approach.